So Takeda wants to do up to $20B in M&A? Welcome to the bidding war for US biotechs
Over the past few months Takeda has unveiled an R&D overhaul that includes a concentration in key US and Japanese hubs and a decision to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
